 | |
- close
- close
|
PR Newswire
Nov 3
Comment
ATLANTA, Nov. 3 /PRNewswire/ -- UCB, an active participant in the epilepsy community for more than a decade, is proudly launching a variety of patient-centered initiatives in honor of Epilepsy Awareness Month in November. These programs are the
PR Newswire
Oct 26
Comment
SAN DIEGO, Oct. 26 /PRNewswire/ -- New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients
Marketwire
Oct 22
Comment
BRUSSELS, BELGIUM -- (Marketwire) -- 10/22/09 -- * Financial performance in line with expectations * Strong early roll-out of major new products Cimzia®, Vimpat® and Neupro® * Diversification of debt begun with successful offering of EUR 500
PR Newswire
Oct 21
Comment
ATLANTA, Oct. 21 /PRNewswire/ -- UCB today announced the 31 recipients of the fourth annual UCB Crohn's Scholarship, awarded to outstanding students of all ages who are living beyond the boundaries of Crohn's disease. To date, the company has granted
FiercePharma
Oct 20
Comment
U.K. cost-effectiveness watchdog NICE says it's "minded not to recommended" the UCB drug Cimzia as a treatment option for rheumatoid arthritis, citing uncertainty embedded in economic models submitted by the company. Report
PR Newswire
Oct 10
Comment
PHILADELPHIA, October 10 /PRNewswire-FirstCall/ -- For U.S. Media Only - U.S. women living with rheumatoid arthritis demand more 'good days' - 68 percent of women living with rheumatoid arthritis look for new pain relief therapies to help them cope -
Stock Blog Hub
Oct 8
Comment
Yesterday, Enzon Pharma (ENZN) announced the European Commission approval of UCB’s Cimzia (certolizumab pegol) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Cimzia utilizes Enzon's PEGylation...
StreetInsider.com
Oct 6
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Enzon+Pharmaceuticals+%28ENZN%29+has+Cimzia+Approved+by+Eurpoean+Commission/4997916.html for the full story.
TheStreet.com
Oct 6
Comment
Epratuzumab data won't be presented at next week's rheumatology meeting.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| ||||||
|
|
